USE OF IBRUTINIB TO TREAT EGFR MUTANT CANCER

摘要

Provided herein are methods of using irreversible BTK inhibitors, such as, for example, ibrutinib (PCI-32765), to treat EGFR mutant cancers, HER2 amplified cancers, and/or HER2 overexpressing cancers.